Auxilium Pharmaceuticals to Present at the J.P. Morgan 2013 Healthcare
MALVERN, Pa., Jan. 3, 2013
MALVERN, Pa., Jan. 3, 2013 /PRNewswire/ --Auxilium Pharmaceuticals, Inc.
(NASDAQ: AUXL) today announced that executive management will participate in
the J.P. Morgan 2013 Healthcare Conference to be held January 7-10, 2013 at
the Westin St. Francis Hotel in San Francisco, CA. Mr. Adrian Adams, Chief
Executive Officer and President, is scheduled to present an overview of the
Company and its product pipeline at 4:00 p.m. PT on Wednesday, January 9,
The presentation slides to be used during the call will be available on the
"For Investors" section of the Auxilium web site under the "Presentations" tab
on January 7, 2013. The presentation and the presentation slides will be
simultaneously web cast on the "For Investors" section of the Auxilium web
site under the "Events" tab on January 9, 2013. A question and answer session
will follow the presentation and will be webcast. To access the live webcast,
please log on to Auxilium's site approximately fifteen minutes prior to the
presentation to register and download any necessary audio software. The
presentation replay will be available for ninety days after the event.
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum)
for the treatment of adult DC patients with a palpable cord in the U.S. GSK
co-promotes Testim with Auxilium in the U.S. Ferring International Center S.A.
markets Testim in certain countries of the EU and Paladin Labs Inc. markets
Testim in Canada. Pfizer has marketing rights for XIAPEX® (the EU tradename
for collagenase clostridium histolyticum) in 46 countries in Eurasia through
April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial
rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development
and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. The
sBLA for XIAFLEX for the treatment of PD was submitted to the FDA on November
6, 2012 and has been accepted for Standard review with a PDUFA date of
September 6, 2013. Additionally, collagenase clostridium histolyticum (CCH) is
in phase IIa of development for the treatment of Frozen Shoulder syndrome
(adhesive capsulitis) and phase Ib of development for the treatment of
cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights
to pursue additional indications for CCH. For additional information, visit
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
This release contains "forward-looking-statements" within the meaning of The
Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the J.P. Morgan 2013
Healthcare Conference; and products in development for Peyronie's disease,
Frozen Shoulder syndrome and cellulite; and all other statements containing
projections, statements of future performance or expectations, our beliefs or
statements of plans or objectives for future operations (including statements
of assumption underlying or relating to any of the foregoing). Forward-looking
statements can generally be identified by words such as "believe," "appears,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and other words and terms of similar meaning in
connection with any discussion of projections, future performance or
expectations, beliefs, plans or objectives for future operations (including
statements of assumption underlying or relating to any of the foregoing).
Actual results may differ materially from those reflected in these
forward-looking statements due to various factors, including further
evaluation of clinical data, results of clinical trials, decisions by
regulatory authorities as to whether and when to approve drug applications,
and general financial, economic, regulatory and political conditions affecting
the biotechnology and pharmaceutical industries and those discussed in
Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the
year ended December 31, 2011 and in Auxilium's Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012, which are on file with the
Securities and Exchange Commission (the "SEC") and may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of Auxilium's home page on the Internet at
http://www.Auxilium.com under the heading "For Investors -- SEC Filings."
There may be additional risks that Auxilium does not presently know or that
Auxilium currently believes are immaterial which could also cause actual
results to differ from those contained in the forward-looking statements.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not rely on any
such factors or forward-looking statements.
In addition, forward-looking statements provide Auxilium's expectations, plans
or forecasts of future events and views as of the date of this release.
Auxilium anticipates that subsequent events and developments will cause
Auxilium's assessments to change. However, while Auxilium may elect to update
these forward-looking statements at some point in the future, Auxilium
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Auxilium's assessments as
of any date subsequent to the date of this release.
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
SOURCE Auxilium Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.